High Dose Melphalan and Stem Cell Transplantation in Patients on Dialysis Due to AL Amyloidosis and Monoclonal Immunoglobulin Deposition Disease
• HDM/SCT is valuable for selected patients with AL amyloidosis and MIDD associated ESRD• 5-year OS was 54% and associated with achievement of CR after HDM/SCT• Treatment-related mortality occurred in 8% of patients• Common grade 3/4 non-hematologic toxicities were infections, mucositis and pulmonary complications
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Felipe Batalini, Laura Econimo, Karen Quillen, J. Mark Sloan, Shayna Sarosiek, Dina Brauneis, Andrea Havasi, Lauren Stern, Laura Dember, Vaishali Sanchorawala Source Type: research
More News: Amyloidosis | Biology | Dialysis | Hematology | Stem Cell Therapy | Stem Cells | Toxicology | Transplants